PTGX
Protagonist Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$134.27-4.71%
Price as of Jul 20, 2026
PTGX growth
Protagonist Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -64.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- +86.6%
- EBITDA
- +65.6%
- EPS
- +256.6%
Three-year CAGR
- Revenue
- +20.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -69.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.